Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02204267

Recruitment Status : Completed

First Posted : July 30, 2014

Last Update Posted : November 13, 2020

Sponsor:

Collaborator:

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Information provided by (Responsible Party):

Matthias Endres, Charite University, Berlin, Germany

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	May 2020
Actual Study Completion Date :	October 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Haeusler KG, Kirchhof P, Heuschmann PU, Laufs U, Busse O, Kunze C, Thomalla G, Nabavi DG, Röther J, Veltkamp R, Endres M. Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. Am Heart J. 2016 Feb;172:19-25. doi: 10.1016/j.ahj.2015.10.010. Epub 2015 Oct 21.

To Top